Agenus Inc. (AGEN) Receives Average Recommendation of “Buy” from Brokerages
Agenus Inc. (NASDAQ:AGEN) has received an average rating of “Buy” from the seven brokerages that are currently covering the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.20.
A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Maxim Group restated a “buy” rating and issued a $7.00 target price on shares of Agenus in a research note on Thursday, July 28th. Jefferies Group restated a “buy” rating on shares of Agenus in a research note on Tuesday, August 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Agenus in a research note on Sunday, July 31st.
Shares of Agenus (NASDAQ:AGEN) traded down 3.66% during midday trading on Thursday, hitting $6.32. 864,211 shares of the company traded hands. Agenus has a 52 week low of $2.61 and a 52 week high of $7.49. The stock’s market capitalization is $549.28 million. The company has a 50-day moving average price of $6.69 and a 200-day moving average price of $5.01.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/agenus-inc-agen-receives-average-recommendation-of-buy-from-brokerages.html
Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.01. The business had revenue of $6.59 million for the quarter, compared to the consensus estimate of $5.12 million. Agenus had a negative net margin of 328.53% and a negative return on equity of 138.27%. Analysts anticipate that Agenus will post ($1.27) earnings per share for the current fiscal year.
In other news, Director Ulf Wiinberg bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was bought at an average price of $6.29 per share, with a total value of $188,700.00. Following the completion of the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $188,700. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. BlackRock Advisors LLC boosted its position in Agenus by 2.2% in the second quarter. BlackRock Advisors LLC now owns 34,250 shares of the company’s stock worth $139,000 after buying an additional 722 shares in the last quarter. Blair William & Co. IL boosted its position in Agenus by 45.9% in the second quarter. Blair William & Co. IL now owns 59,700 shares of the company’s stock worth $189,000 after buying an additional 18,775 shares in the last quarter. Creative Planning boosted its position in Agenus by 2.8% in the second quarter. Creative Planning now owns 64,171 shares of the company’s stock worth $260,000 after buying an additional 1,762 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Agenus by 56.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 77,931 shares of the company’s stock worth $324,000 after buying an additional 28,187 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Agenus by 15.2% in the second quarter. Rhumbline Advisers now owns 94,272 shares of the company’s stock worth $382,000 after buying an additional 12,417 shares in the last quarter. 40.63% of the stock is owned by institutional investors and hedge funds.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.